4D Molecular Therapeutics, Inc. 10-Q filing
Filed 2025-11-10 · Report date 2025-09-30 · 2025
Filing metadata
- Accession number
- 0001193125-25-273343
- Form type
- 10-Q
- CIK
- 0001650648
- Primary document
- https://www.sec.gov/Archives/edgar/data/1650648/000119312525273343/fdmt-20250930.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for 4D Molecular Therapeutics, Inc..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Revenue | $119,000 | - | - |
| Operating Income | $-174.3M | - | - |
| Net Income | $-159.5M | - | - |
| Eps Basic | -2.85 | - | - |
| Eps Diluted | -2.85 | - | - |
| Cash And Equivalents | $48.6M | - | - |
| Total Assets | $424.0M | - | - |
| Total Liabilities | $55.0M | - | - |
| Shareholders Equity | $369.0M | - | - |
| Operating Cash Flow | $-137.6M | - | - |
| Capital Expenditures | $606,000 | - | - |